Investor Relations

StemRIMInvestor Relations

Investor News

November 11, 2026	Timely Disclosure Information	StemRIM Announces Issuance of New Shares as Remuneration for Restricted Stock
November 9, 2026	Timely Disclosure Information	Patent Registration (Australia) for Redasemtide in Fatty Liver and NASH
November 9, 2026	Timely Disclosure Information	Patent Registration (Israel) for Redasemtide in Cartilage Disorders
October 30, 2026	Timely Disclosure Information	Presentation Material for Business Plan and Growth Potential

IR Library

Stock Information

Investor Library

This list of analysts was prepared based on material that was available at the time of writing. Therefore, please note that there may be other analysts who have not been included in this list, and that some of the information may not be the latest.
Please note that the analysts have conducted their own analyses of the Company’s performance, businesses, products and technologies, and have developed their own forecasts. These processes do not in any way involve the Company or the management of the Company.
Furthermore, the management of StemRIM does not endorse or concur with the forecasts, opinions and recommendations of these analysts. Thus, we cannot take any responsibility regarding the consistency of such information.
The provision of this list is explicitly for the purpose of introducing analysts of external companies or research-related institutions that have undertaken analyses and forecasts of our corporate performance. This is not for the purpose of soliciting sales of the Company’s stock.
Please note that decisions regarding the purchase of shares are solely up to the investors themselves.